Showing results (1-10 of 188) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Oral chemotherapy: rationale and future directionsM D DeMario, M J RatainOncology (Williston Park, N.Y.)|February 12, 1998
Rationale for phase I study of UFT plus leucovorin and oral JM-216M D DeMario, M J RatainCancer Chemotherapy and Pharmacology|April 1, 1999
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 daysM D DeMario, M J Ratain, N J Vogelzang, et al.Seminars in Oncology|September 5, 1998
Lymphomas in the immunocompromised patientM D DeMario, D N LiebowitzSeminars in Oncology|August 1, 1992
Therapeutic relevance of pharmacokinetics and pharmacodynamicsM J RatainEuropean Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Update on pharmacogenetics in cancer chemotherapyF Innocenti, M J RatainCancer Chemotherapy and Pharmacology|January 1, 1994
Pharmacodynamics and long-term toxicity of etoposideK Kobayashi, M J RatainInvestigational New Drugs|June 8, 2001
Body surface area as a determinant of pharmacokinetics and drug dosingM Sawyer, M J RatainJournal of the National Cancer Institute|February 3, 1993
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precisionR Mick, M J RatainEuropean Journal of Cancer (Oxford, England : 1990)|January 20, 1999
Pharmacogenetics and cancer chemotherapyL Iyer, M J RatainPageof 19